Tuesday, November 12, 2019 11:00 am EDT | Complimentary Webinar
Choosing the right drug target: How to avoid late stage failures and increase chances of success
Loading...
Whether prioritizing internal candidates for further development or deciding which early projects to in-license, choosing the right target is essential to increasing the chance of successfully launching your drug. Selecting the wrong target in early drug discovery can waste time and money, and eventually result in failure of the program. Winning the race to be first-in-class is potentially lucrative but inherently risky, while being best-in-class requires an asset to be clearly differentiated from the competition.
Learn how you can better evaluate targets to avoid wasting resources and missing opportunities while minimizing risks. Join this webinar to discover best practice approaches and data-driven options.
A scientist will discuss how you can:
-
Evaluate the biological evidence for linking a target to a disease of interest
-
Monitor the early drug-target landscape and be alerted to potential future threats
-
Establish a benchmark for “best-in-class” efficacy and safety
-
Make data-driven decisions based on scientific and commercial factors
Speaker:
Carolyn Finch
Solution Scientist, Clarivate Analytics
Carolyn Finch has more than 25 years’ experience in the life sciences patent and scientific information industry working as a patent analyst, a trainer and a solutions consultant. Since 2008, Carolyn has worked closely with pharmaceutical/biotech companies globally to understand their research and business needs and align them with appropriate solutions to accelerate their drug discovery.
Dr. Matthew Wampole
Manager, Solution Scientists
Clarivate Analytics
Clarivate Analytics
Dr. Matthew Wampole received his PhD in chemistry from Bryn Mawr College with a focus on computational chemistry. Prior to joining Clarivate, he worked at Thomas Jefferson University as postdoctoral research fellow to develop tumor specific imaging probes for cancer patients with KRAS mutations.
Register below and we'll send the details straight to your inbox.
